Insmed reported encouraging 12-month results from an open-label extension study of treprostinil palmitil inhalation powder (TPIP), a once-daily therapy for pulmonary arterial hypertension (PAH). While the update is supportive for TPIP’s ongoing clinical development, it is based on an extension/open-label setting rather than a pivotal, controlled readout. Overall, the news is modestly positive for INSM’s clinical trajectory.
Insmed reported encouraging 12-month results from an open-label extension study of treprostinil palmitil inhalation powder (TPIP), a once-daily therapy for pulmonary arterial hypertension (PAH). While the update is supportive for TPIP’s ongoing clinical development, it is based on an extension/open-label setting rather than a pivotal, controlled readout. Overall, the news is modestly positive for INSM’s clinical trajectory.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
